{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:35:25Z","timestamp":1787798125670,"version":"build-2784847793"},"reference-count":29,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Baricitinib is an orally administered inhibitor of JAK1 and JAK2 that has been shown to be effective in treating rheumatoid arthritis (<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>). This study was undertaken to analyze changes in lymphocyte cell subsets during baricitinib treatment and to correlate these changes with clinical outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An integrated analysis was conducted by pooling data from 3 completed phase <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> trials comparing placebo with baricitinib treatment (<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">BEAM<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> RA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">BUILD<\/jats:styled-content>, and <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">BEACON<\/jats:styled-content>) and 1 ongoing long\u2010term extension study (<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">BEYOND<\/jats:styled-content>) in patients with active <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> (n = 2,186).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Baricitinib treatment was associated with an early transient increase in total lymphocyte count at week 4, which returned to baseline by week 12. Transient changes within normal reference ranges in T cells and subsets were observed with baricitinib treatment, up to week 104. B cells and relevant subpopulations increased after 4 weeks of baricitinib treatment, with no further increases noted through 104 weeks of treatment. Natural killer (<jats:styled-content style=\"fixed-case\">NK<\/jats:styled-content>) cells temporarily increased after 4 weeks of baricitinib treatment, before decreasing below baseline levels and then stabilizing over time. With baricitinib treatment, few correlations were observed between changes in lymphocyte subsets and clinical end points, and most correlations were also observed within the placebo group. A modest potential association between low <jats:styled-content style=\"fixed-case\">NK<\/jats:styled-content> cell numbers and treatment\u2010emergent infections was observed in the baricitinib 4 mg\/day treatment group, but not for serious infections or herpes zoster.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Overall, these findings demonstrate that changes in lymphocyte subsets were largely within normal reference ranges across the baricitinib phase <jats:styled-content style=\"fixed-case\">III RA<\/jats:styled-content> clinical program and were not associated with increased risk of serious infections.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.40680","type":"journal-article","created":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T02:10:26Z","timestamp":1532916626000},"page":"1923-1932","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Characterization and Changes of Lymphocyte Subsets in Baricitinib\u2010Treated Patients With Rheumatoid Arthritis"],"prefix":"10.1002","volume":"70","author":[{"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[{"name":"University of Occupational and Environmental Health Japan Kitakyushu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[{"name":"University of Glasgow Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Botnar Research Centre and University of Oxford Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Byers","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"de Bono","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Issa","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Macias","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Rogai","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence P.","family":"Rooney","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Schlichting","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H.","family":"Zuckerman","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[{"name":"NIHR Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, and University of Leeds Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004965"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2015.137"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket414"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.167"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.354"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39953"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"issue":"10","key":"e_1_2_8_12_1","article-title":"Characterization of changes in lymphocyte subsets in baricitinib\u2010treated patients with rheumatoid arthritis in two Phase 3 studies [abstract]","volume":"67","author":"Emery P","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-eular.1513"},{"issue":"2","key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2017-eular.1336","article-title":"Characterization of changes in lymphocyte subsets in baricitinib\u2010treated patients with early, DMARD na\u00efve, rheumatoid arthritis in a phase 3 study [abstract]","volume":"76","author":"Takeuchi T","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.51"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13557"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14403"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm401490p"},{"key":"e_1_2_8_20_1","first-page":"318","article-title":"The mechanism of action of tofacitinib\u2013an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge JA","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-eular.2134"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew329"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210104"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210105"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39801"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39808"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20217"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34477"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu363"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30242"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.40680","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.40680","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.40680","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.40680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:48:30Z","timestamp":1759952910000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.40680"}},"subtitle":["An Integrated Analysis"],"short-title":[],"issued":{"date-parts":[[2018,10,22]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1002\/art.40680"],"URL":"https:\/\/doi.org\/10.1002\/art.40680","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,22]]},"assertion":[{"value":"2017-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}